AHPA opposes Dietary Supplement Listing Act
- By: AHPA
- On: 04/27/2022 21:13:24
- In: Regulation / Legislation
April 27, 2022
The American Herbal Products Association (AHPA) is announcing opposition to the Dietary Supplement Listing Act introduced by Senators Richard Durbin (D-IL) and Mike Braun (R-IN) that would establish a requirement for mandatory product listing (MPL) for all dietary supplements marketed in the United States.
AHPA has a significant track record of supporting statutory amendments to the Federal Food, Drug, and Cosmetic Act when they clearly benefit consumers and when such amendments achieve their ends in a manner that minimizes burdens on the regulated trade. But, to date, neither the U.S. Food and Drug Administration (FDA) nor other advocates for MPL have clearly articulated the need for this premarket product listing requirement. In addition, the legislation introduced by Senators Durbin and Braun would create unnecessary, significant, and redundant burdens on industry.
AHPA has emphasized for several years that the current federal regulatory framework for dietary supplements supports the industry and consumers. Further, AHPA has stated this framework provides FDA with all of the authority needed to properly regulate dietary supplements, and thus an MPL requirement is unnecessary. Nothing in this newly introduced legislation has modified these views.
At the same time, AHPA recognizes the interest of FDA and the support of some trade associations and others in establishing an MPL requirement for dietary supplements. We have therefore communicated with FDA, numerous Congressional offices, industry colleagues, and other stakeholders to share alternate suggestions for modernizing the federal laws under which FDA regulates dietary supplements.
We look forward to future opportunities to engage in robust and transparent discussions about how we can work cooperatively to advance health with increased education and broad access to a wide range of safe and well-regulated dietary supplement products.